"Complement C5" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
C5 plays a central role in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C5 is cleaved by C5 CONVERTASE into COMPLEMENT C5A and COMPLEMENT C5B. The smaller fragment C5a is an ANAPHYLATOXIN and mediator of inflammatory process. The major fragment C5b binds to the membrane initiating the spontaneous assembly of the late complement components, C5-C9, into the MEMBRANE ATTACK COMPLEX.
| Descriptor ID |
D003182
|
| MeSH Number(s) |
D12.776.124.486.274.450
|
| Concept/Terms |
Complement C5- Complement C5
- C5, Complement
- C5 Complement
- Complement, C5
- Complement 5
- Complement Component 5
- Component 5, Complement
Complement C5, Precursor- Complement C5, Precursor
- C5, Precursor Complement
- Precursor Complement C5
- Pro-C5
- Pro C5
- Pro-complement 5
- Pro complement 5
- Precursor C5
- C5, Precursor
|
Below are MeSH descriptors whose meaning is more general than "Complement C5".
Below are MeSH descriptors whose meaning is more specific than "Complement C5".
This graph shows the total number of publications written about "Complement C5" by people in this website by year, and whether "Complement C5" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Complement C5" by people in Profiles.
-
Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs. J Manag Care Spec Pharm. 2020 Dec; 26(12-b Suppl):S14-S20.
-
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. JAMA Neurol. 2020 05 01; 77(5):582-592.
-
Complement can neutralize HIV-1 plasma virus by a C5-independent mechanism. Virology. 1998 Sep 01; 248(2):173-81.